Warning: fopen(/home/virtual/pediatrics/journal/upload/ip_log/ip_log_2024-12.txt) [function.fopen]: failed to open stream: Permission denied in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 93

Warning: fwrite(): supplied argument is not a valid stream resource in /home/virtual/pediatrics/journal/ip_info/view_data.php on line 94
Growth Promoting Effect of Recombinant methionyl-Growth Hormone in Children with Chronic Renal Failure

Journal of the Korean Pediatric Society 1992;35(10):1355-1360.
Published online October 15, 1992.
Growth Promoting Effect of Recombinant methionyl-Growth Hormone in Children with Chronic Renal Failure
Heon Seok Han1, Yong Choi2, Hyung Ro Moon2
1Department of Pediatrics, Chonbuk National University Medical School, Cheongju, Korea
2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
2Department of Pediatrics, Seoul National University College of Medicine, Seoul, Korea
만성 신부전 환자에서 성장 호르몬의 성장 촉진에 관한 연구
한헌석1, 최용2, 문형로2
1충북대학교 의과대학 소아과학교실
2서울대학교 의과대학 소아과학교실
2서울대학교 의과대학 소아과학교실
Abstract
The authors studied the growth-promoting effect of yeast-derived methionyl-hGH in short statured children with uremic chronic renal failure. The subjects were prepubertal chronic renal insufficient patients whose height standard deviation scores were below -2.0. Two boys and two girls participated in this study. Chronic renal insufficiency was the only cause for the short stature. HGH was given to the subjects in dose of 0.75 U/kg/wk subcutaneously in three divided doses for the first six months, and then in six divided doses for the next six months. The height, weight, complete blood count and blood chemistries were checked every 3 months, and bone age, thyroid functions, IGF-1 and growth hormone antibody were tested every 6 months. The mean height SDS before treatment, at 6 months, and at 12 months of therapy was -4.43, -4.42 and -4.05, respectively. The height velocity before therapy, at 6 months and at 12 mo of therapy was 2.68, 5.43 and 5.90 cm/yr, respectively. The height velocity differences were -2.05 before therapy, +1.43 at 6 mo, +1.60 cm/yr at 12 mo of therapy. The mean bone age advancement was 0.9 yr in a year of therapy. The growth hormone antibody was not detected during therapy with the preparation. These results suggest that administration of yeast-derived methiony-hGH is effective in promoting linear growth for the short statured uremic prepubertal children.
Key Words: Human growth hormone, Chronic renal failure, Short stature


METRICS Graph View
  • 2,477 View
  • 6 Download